Chronic graft-versus-host disease (GVHD) remains a common and potentially lifethreatening complication of allogeneic hematopoietic stem cell transplantation (HCT). 
Introduction
The prevalence and severity of chronic GVHD have increased during the past 2 decades in association with the increasing use of HCT for treatment of older age patients, the widespread use of mobilized blood cells instead of marrow for grafting, and improvements in survival during the first several months after allogeneic HCT. [1] [2] [3] [4] [5] [6] Pathophysiologic understanding of chronic GVHD is emerging, 7;8 but the long-standing reliance on prednisone described as the mainstay of treatment in Vogelsang's "How I treat" review in 2001 has persisted to the present. 9 The 2005 National Institute of Health (NIH) Consensus Conference developed a framework for characterizing the pleomorphic manifestations of chronic GVHD. The consensus project defined minimal criteria for the clinical diagnosis, emphasized differences in the clinical manifestations of chronic and acute GVHD, established criteria for scoring the severity of clinical manifestations in affected organs, and proposed new categories for describing overall disease severity and indications for treatment. 10 The consensus project also proposed measures for monitoring disease progression and response to therapy and provided other information for purposes of clinical trials. [11] [12] [13] In 2014, the NIH Conference was reconvened, and revisions are under consideration to update the recommendations based on available evidence and insights from clinical application of the original recommendations.
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Chronic GVHD has a wide range of pleomorphic manifestations, and many complications can emerge from both the disease and its treatment. A dedicated multidisciplinary team approach with relevant expertise is necessary in order to provide the best care for patients with a chronic illness that can have devastating effects of For personal use only. on May 1, 2017 . by guest www.bloodjournal.org From quality of life. Our approach to treatment emphasizes the importance of early recognition in the management of chronic GVHD, with respect to making the initial diagnosis, monitoring the response to initial treatment, and preventing complications and disability. Nuances applicable only to children are not addressed in this review.
Case summary
A 45 year-old man received growth factor-mobilized blood cells from an HLA-matched unrelated male donor after conditioning with 12 Gy total body irradiation and cyclophosphamide for treatment of acute myeloid leukemia with persistent disease. He received methotrexate and tacrolimus for immunosuppression after HCT. He developed acute GVHD of the skin and gut, which resolved after treatment with steroid cream and oral beclomethasone and budesonide. Because malignant cells persisted after HCT, treatment was administered with azacytidine, and immunosuppression with tacrolimus was withdrawn by day 100, 3 months earlier than originally planned.
Malignant cells disappeared, but 7 months after HCT and 2 months after the 3 rd cycle of azacytidine, he was diagnosed with severe chronic GVHD (NIH global score).
Affected sites included the skin (erythematous rash involving >50% body surface area), mouth (ulcers and lichenoid features), fasciae (wrist tightness and leg edema), liver (alanine aminotransferase twice the normal upper limit with normal total serum bilirubin concentration) and eosinophilia (1,800/μl). Forced expiratory volume in the first second (FEV1) was 79% of predicted, and the ratio of FEV1 to forced vital capacity (FVC) was 78% of predicted, representing an absolute 8% decline from the baseline before HCT.
Treatment was started with prednisone at 1 mg/kg/day, and antibiotic prophylaxis was administered to prevent Pneumocystis pneumonia and infection with encapsulated 
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The extent and severity of sclerosis remained stable for 3 months. Sclerosis then began to progress, involving approximately 50% of BSA with a Rodnan score of 28 after 6 months of treatment with imatinib. The patient met the criteria for crossover according to the study design, and he was treated with 2 cycles of rituximab, 375 mg/m 2 /week for 4 weeks per cycle. Due to hypertension and hyperglycemia, the dose of prednisone was gradually tapered to 40 mg every other day within 6 months. The patient subsequently reported improved flexibility, and after 7 months, sclerosis remained stable with a Rodnan score of 26. 
Diagnosis and Evaluation
Manifestations of chronic GVHD can resemble autoimmune or other immune-mediated disorders such as scleroderma, Sjögren syndrome, primary biliary cirrhosis, bronchiolitis obliterans, immune cytopenias, and chronic immunodeficiency. Manifestations typically appear within the first year after HCT, most often when doses of immunosuppressive medications are weaned. The disease can begin as early as 2 months and as late as 7 years after HCT, although onset at more than 1 year from HCT occurs in less than 10% of cases. 46 Chronic GVHD should be suspected at the onset of any perturbation in laboratory tests, symptoms or signs, especially during the first year after HCT.
Conversely, not every problem after allogeneic HCT represents chronic GVHD. Other conditions such as eczema, iron overload, hypothyroidism, adrenal insufficiency, infections or drug effect can be misdiagnosed as chronic GVHD. 47 For personal use only. Close serial monitoring of all organ systems is essential in order to ensure early detection, recognition and intervention directed toward reversing or preventing progression of chronic GVHD manifestations and treatment-associated toxicities. In particular, periodic pulmonary function tests are essential for early detection of lung involvement manifested as BOS, since this complication has an insidious onset, and patients may remain asymptomatic until considerable lung function has been lost. We recommend complete pulmonary function testing in all patients before HCT and at approximately 3 months after HCT as a baseline for future comparisons (Table 4) . 
Treatment
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Treatment of chronic GVHD is intended to produce a sustained benefit by reducing symptom burden, controlling objective manifestations of disease activity and preventing damage and disability, without causing disproportionate toxicity or harms related to the treatments themselves. The long-term goal of GVHD treatment is the development of immunological tolerance, indicated by successful withdrawal of all immunosuppressive treatment without recurrence or clinically significant exacerbation of disease manifestations. The current therapeutic approach functions primarily to prevent immune-mediated damage, while awaiting the development of tolerance. Evidence to suggest that current treatments accelerate the development of immunological tolerance is lacking. Optimal treatment of chronic GVHD requires a multidisciplinary team approach that includes transplantation specialists, a primary health care provider, organ-specific consultants, nurses, and ancillary services such as social services, vocational specialists, patient and family support groups and systems.
Systemic therapy for at least 1 year is generally indicated for patients who meet criteria for moderate-to-severe disease according to the NIH consensus criteria: involvement of 3 or more organs, moderate or severe organ involvement in any organ, or any lung involvement.
10;51 Systemic treatment is also generally indicated for patients with less severe disease if high-risk features such as thrombocytopenia, hyperbilirubinemia or onset during corticosteroid treatment are present.
2;10;52-54
Symptomatic mild chronic GVHD is often treated with topical therapies alone.
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Topical agents may also be used as adjuncts to systemic therapy to improve and accelerate local response. Comprehensive reviews of topical therapies have been published previously. affected organs or sites, the severity of disease manifestations, the presence of health problems that might be exacerbated by the treatment, possible drug interactions, the intensity of the monitoring needed, and factors that affect access to the treatment such as travel, distance and cost.
Primary systemic treatment
Management of chronic GVHD has relied on corticosteroids as the mainstay of treatment for more than 3 decades. Systemic treatment typically begins with prednisone at 0.5 to 1mg/kg/day, followed by a taper to reach an alternate-day regimen, with or without cyclosporine or tacrolimus. The efficacy of alternate-day versus daily administration of corticosteroids has been reported in pediatric renal transplantation but has not been tested in HCT. 55 Prolonged systemic corticosteroid treatment causes significant toxicity, including weight gain, bone loss, myopathy, diabetes, hypertension, mood swings, cataract formation, and increased risk of infection. Many of these toxicities can be mitigated by alternate-day administration of corticosteroids. Alternateday administration also has an important role in facilitating adrenal recovery long before the end of treatment. In a recent prospective study, the average dose of prednisone was tapered to 0.20 -0.25 mg/kg/day or 0.4 -0.5 mg/kg every other day within 3 months after starting treatment. 56 Medications used for treatment of chronic GVHD should be withdrawn gradually one at a time after the disease has resolved. As a general principle, withdrawal of systemic treatment should begin with the medication that is most likely to cause long-term toxicity. Withdrawal of prednisone should generally precede withdrawal of a calcineurin inhibitor, unless continued treatment with the calcineurin inhibitor threatens to cause intolerable or irreversible toxicity.
Strategies for tapering the dose of prednisone vary considerably, but as a general principle, efforts should be made to use the minimum dose that is sufficient to control GVHD manifestations ( Figure 2 ). In practice, this means that prednisone doses should be decreased progressively in patients who have had a complete response or a very good partial response, and tapering should continue until manifestations begin to recur or show evidence of exacerbation. A prototypic taper schedule (Table 5) is designed to approximate a 20 -30% dose reduction every 2 weeks, with smaller absolute decrements toward the end of the taper schedule. Toxicity associated with the administration of prednisone may require dose adjustments.
A physician or advanced practitioner should examine the patient before each reduction of the prednisone dose. If exacerbation or recurrence of chronic GVHD is evident at any step of the taper, the dose of prednisone should be increased promptly by 2 levels, with daily administration for 2 -4 weeks, followed by resumption of alternate day administration. Treatment should then be continued for at least 3 months before attempting to resume the taper. Cycles of attempted tapering and dose escalation should be repeated as needed until the dose reaches 0.10 mg/kg/day, which equates to adrenal replacement therapy. Administration of prednisone may be discontinued after a minimum of at least 4 weeks of treatment at a dose of 0.10 mg/kg every other day. Some patients have recurrent symptoms with doses at or below 0.10 mg/kg every other day, and in this situation, treatment with very low prednisone doses may be required for a year or more.
Combination therapy with other immunosuppressive agents is often considered in hopes of minimizing toxicity caused by prolonged corticosteroid treatment. showed no statistically significant differences in survival or the duration of treatment.
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The incidence of avascular necrosis was lower in the cyclosporine plus prednisone arm, suggesting that cyclosporine could have had a steroid-sparing effect, but steroid doses across time were not measured in this study. Results are pending from a recent randomized, multi-center phase II -III clinical trial comparing prednisone and sirolimus with or without a calcineurin inhibitor for initial treatment of chronic GVHD. Premature closure of this trial at the end of phase II suggests that the expected benefit of omitting the calcineurin inhibitor was not observed. Wherever possible, clinical trials should be considered as the first option for initial systemic treatment of chronic GVHD.
Secondary systemic treatment
Approximately 50 -60% of patients with chronic GVHD require secondary treatment within 2 years after initial systemic treatment. 61;62 Indications for secondary treatment include worsening manifestations of chronic GVHD in a previously affected organ, development of signs and symptoms of chronic GVHD in a previously unaffected organ, absence of improvement after one month of standard primary treatment, inability to decrease prednisone below 1mg/kg/ day within 2 months, or significant treatmentrelated toxicity. Numerous clinical trials have been carried out to evaluate approaches for secondary treatment of chronic GVHD. Reports from retrospective and prospective studies often indicate high response rates, but results are difficult to interpret because of deficiencies in study design.
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No consensus has been reached regarding the optimal choice of agents for secondary treatment of chronic GVHD, and the published literature provides little useful guidance. Therefore, clinical management requires an empirical approach, as illustrated in the case summarized above. Treatment choices are based on physician experience, ease of use, need for monitoring, risk of toxicity and potential exacerbation of pre-existing co-morbidity. 63, 64 Options for secondary treatment have been recently reviewed and are summarized in Table 6 .
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Ancillary and Supportive care
Ancillary and supportive care therapies are commonly employed in addition to systemic treatment for GVHD, although in some cases, their use may circumvent the need for systemic treatment or allow doses of systemic agents to be reduced. A detailed list of site-specific therapies has been reported elsewhere. 
Prognosis and outcomes
Duration of treatment
Approximately 50% of patients are cured within 7 years after starting systemic For personal use only. on May 1, 2017. by guest www.bloodjournal.org From respect to chronic GVHD: a higher incidence, a higher risk of fasciitis and development of fibrotic manifestations affecting the skin and joints, and a longer time to resolution of the disease, development of immunological tolerance and withdrawal of systemic treatment. 48 The median duration of systemic treatment for chronic GVHD is approximately 2 years in patients who had HCT with marrow cells and approximately 3.5 years in those who had HCT with mobilized blood cells.
Graft-versus-leukemia associated with chronic GVHD
Chronic GVHD is associated with a reduced risk of recurrent malignancy after 
GVHD.
56 Therefore, the intensity of treatment should be calibrated periodically by lowering the dose of immunosuppressive medications to levels that allow disease manifestations to begin emerging before increasing the dose, as described above (Figure 2 ). Review of systems (see Table 3 for chronic GVHD-specific questions)
Future perspectives
Every clinic visit Every clinic visit
Physical examination
Complete skin examination (look, touch, pinch) For personal use only. on May 1, 2017. by guest www.bloodjournal.org From
